Somatostatin receptor expression in thymic tumors

Diego Ferone; Liliana Montella; Annarosaria De Chiara; Leo J. Hofland; Steven W J Lamberts; Giovannella Palmieri

doi:10.2735/3453

Somatostatin receptor expression in thymic tumors

Diego Ferone, Liliana Montella, Annarosaria De Chiara, Leo J. Hofland, Steven W J Lamberts, Giovannella Palmieri

Research output: Contribution to journal › Article › peer-review

Abstract

Detection of thymic tumors by [¹¹¹In-DTPA⁰]octreotide scintigraphy and the antitumor effect exerted by somatostatin (SS) analogs suggest significant expression of SS receptors (SSRs) in these tumors. We measured SSR subtype (sst)_2A and sst₃ expression by immunohistochemistry (IHC) in 14 thymic tumors previously studied by SSR scintigraphy (SRS). Scintigraphy showed significant [¹¹¹In-DTPA ⁰]octreotide uptake in 13/14 tumors (tumor-to-background ratios: 1.4-to 6-fold). By IHC, 4 tumors were positive for sst_2A and sst ₃; two for sst_2A and five tumors for sst₃. Three tumors were completely negative. Overall, 11/14 (approximately 78% of cases) expressed at least one SSR subtype. Staining was highly heterogeneous: sst_2A was confined to malignant epithelial cells or within stromal structures, and sst₃ was predominantly associated with thymocytes. SRS provides immediate visualization of primary and metastatic lesions, while IHC reveals SSR subtype expression. This joined approach could help to select SS analogs beneficial for therapy.

Original language	English
Pages (from-to)	3304-3309
Number of pages	6
Journal	Frontiers in Bioscience
Volume	14
Issue number	9
DOIs	https://doi.org/10.2735/3453
Publication status	Published - Jan 1 2009

Keywords

Immunohistochemistry
Neuroendocrine tumors
Octreotide
Somatostatin
Somatostatin receptors
Thymic tumors

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Immunology and Microbiology(all)
Medicine(all)

Access to Document

10.2735/3453

Cite this

@article{00a8bdc8204b4e7bac88aa145ec0b7bd,

title = "Somatostatin receptor expression in thymic tumors",

abstract = "Detection of thymic tumors by [111In-DTPA0]octreotide scintigraphy and the antitumor effect exerted by somatostatin (SS) analogs suggest significant expression of SS receptors (SSRs) in these tumors. We measured SSR subtype (sst)2A and sst3 expression by immunohistochemistry (IHC) in 14 thymic tumors previously studied by SSR scintigraphy (SRS). Scintigraphy showed significant [111In-DTPA 0]octreotide uptake in 13/14 tumors (tumor-to-background ratios: 1.4-to 6-fold). By IHC, 4 tumors were positive for sst2A and sst 3; two for sst2A and five tumors for sst3. Three tumors were completely negative. Overall, 11/14 (approximately 78% of cases) expressed at least one SSR subtype. Staining was highly heterogeneous: sst2A was confined to malignant epithelial cells or within stromal structures, and sst3 was predominantly associated with thymocytes. SRS provides immediate visualization of primary and metastatic lesions, while IHC reveals SSR subtype expression. This joined approach could help to select SS analogs beneficial for therapy.",

keywords = "Immunohistochemistry, Neuroendocrine tumors, Octreotide, Somatostatin, Somatostatin receptors, Thymic tumors",

author = "Diego Ferone and Liliana Montella and {De Chiara}, Annarosaria and Hofland, {Leo J.} and Lamberts, {Steven W J} and Giovannella Palmieri",

year = "2009",

month = jan,

day = "1",

doi = "10.2735/3453",

language = "English",

volume = "14",

pages = "3304--3309",

journal = "Frontiers in Bioscience - Landmark",

issn = "1093-9946",

publisher = "Frontiers in Bioscience",

number = "9",

}

TY - JOUR

T1 - Somatostatin receptor expression in thymic tumors

AU - Ferone, Diego

AU - Montella, Liliana

AU - De Chiara, Annarosaria

AU - Hofland, Leo J.

AU - Lamberts, Steven W J

AU - Palmieri, Giovannella

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Detection of thymic tumors by [111In-DTPA0]octreotide scintigraphy and the antitumor effect exerted by somatostatin (SS) analogs suggest significant expression of SS receptors (SSRs) in these tumors. We measured SSR subtype (sst)2A and sst3 expression by immunohistochemistry (IHC) in 14 thymic tumors previously studied by SSR scintigraphy (SRS). Scintigraphy showed significant [111In-DTPA 0]octreotide uptake in 13/14 tumors (tumor-to-background ratios: 1.4-to 6-fold). By IHC, 4 tumors were positive for sst2A and sst 3; two for sst2A and five tumors for sst3. Three tumors were completely negative. Overall, 11/14 (approximately 78% of cases) expressed at least one SSR subtype. Staining was highly heterogeneous: sst2A was confined to malignant epithelial cells or within stromal structures, and sst3 was predominantly associated with thymocytes. SRS provides immediate visualization of primary and metastatic lesions, while IHC reveals SSR subtype expression. This joined approach could help to select SS analogs beneficial for therapy.

AB - Detection of thymic tumors by [111In-DTPA0]octreotide scintigraphy and the antitumor effect exerted by somatostatin (SS) analogs suggest significant expression of SS receptors (SSRs) in these tumors. We measured SSR subtype (sst)2A and sst3 expression by immunohistochemistry (IHC) in 14 thymic tumors previously studied by SSR scintigraphy (SRS). Scintigraphy showed significant [111In-DTPA 0]octreotide uptake in 13/14 tumors (tumor-to-background ratios: 1.4-to 6-fold). By IHC, 4 tumors were positive for sst2A and sst 3; two for sst2A and five tumors for sst3. Three tumors were completely negative. Overall, 11/14 (approximately 78% of cases) expressed at least one SSR subtype. Staining was highly heterogeneous: sst2A was confined to malignant epithelial cells or within stromal structures, and sst3 was predominantly associated with thymocytes. SRS provides immediate visualization of primary and metastatic lesions, while IHC reveals SSR subtype expression. This joined approach could help to select SS analogs beneficial for therapy.

KW - Immunohistochemistry

KW - Neuroendocrine tumors

KW - Octreotide

KW - Somatostatin

KW - Somatostatin receptors

KW - Thymic tumors

UR - http://www.scopus.com/inward/record.url?scp=63849297153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849297153&partnerID=8YFLogxK

U2 - 10.2735/3453

DO - 10.2735/3453

M3 - Article

C2 - 19273275

AN - SCOPUS:63849297153

VL - 14

SP - 3304

EP - 3309

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 9

ER -

Somatostatin receptor expression in thymic tumors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this